Company profile
Applied Biosciences Corp.
OTC: APPB · Healthcare · Drug Manufacturers - Specialty & Generic
#907 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ 19GM —SS 32
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), listing tenure · ↓ market scale, disclosure history
Methodology →Revenue TTM
$859.9k
Rev growth YoY (TTM)
+75.3%
Net income (FY)
-$2.7M
Employees
25
as of 2026-07-12
Market cap
$1.4k
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$707.1k$707.1k2019
Net income-$2.7M-$2.7M2019
Operating income-$2.6M-$2.6M2019
Total assets$3.7M$3.7M2019
Equity$2.1M$2.1M2019
Revenue trend
FY2017 – FY2019 · USD
FY17
FY18
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Applied Biosciences Corp.’s revenue?
Applied Biosciences Corp. booked $707.1k in FY2019 revenue, growing 258% year over year — faster than 91% of Healthcare companies we track, at a -378.9% net margin.
Peers · Healthcare
Dogecoin Cash, Inc.39DAvivagen Inc.——Relevium Technologies Inc.——Lexaria Bioscience Corp.44DHarvard Apparatus Regenerative Technology Inc.41DAdia Nutrition, Inc.29DNeighbors
Los Angeles →Key facts
CEOChristopher Michael Bridges
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBeverly Hills, CA
ExchangeOTC: APPB
Employees25
IPO date2016-02-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.